Journal articleMol Cancer Ther2021
Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
- Journal
- Mol Cancer Ther
- Published
- 2 December 2020
- Citations
- 38
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 5
- Administrative Supplement P30 Cancer Center Support Grant (CCSG): Phase 1 Study of Olaparib in Combination with Durvalu… P30CA046592↗
- Translational Research in GI Cancer P50CA130810↗
- Selective Sensitization of Pancreatic Cancer to Therapy by Chk1 and PARP1 Inhibit R01CA163895↗
- Targeting the DNA damage response in combination with radiation to induce innate immunity and improve immunotherapy eff… R01CA240515↗
- Sensitization to Chemoradiation by Therapeutic Targeting of the DNA Damage Response U01CA216449↗